This guide is individual in a seri...

This guide is individual in a series that furnishs evidence-based tools to assist family physicians in improving their decision-making at the point of care.

Clinical Question

What is the best way to initiate oral anticoagulation therapy with warfarin (Coumadin)?

Evidence Summary

Many physicians continue to use clinical sense alone as the basis for initiating and adjusting warfarin dosages in patients who require oral anticoagulation. A number of studies have validated approaches to initiation of anticoagulation that pro-vide more rapid anticoagulation with les chance of complications. This article reviews these decision-support tools. A coming events Point-of-Care Guide will address evidence-based guidelines for adjustments to the warfarin dosage in patients in succession long-term therapy.

The sum of two units widely used dosing options forward the initiation of warfarin therapy are 5 mg and 10 mg for day. A small study (1) randomized 49 inpatients to receive initial doses of 5 mg or 10 mg with following adjustments made according to an algorithm that was not included in the article. All patients were simultaneously treated with heparin. Although patients in the 10-mg clump achieved a therapeutic level (International Normalized Ratio [INR] greater than 20) more rapidly, they were four times more likely to have a supratherapeutic INR on a level at 60 hours and to require administration of vitamin K for reversal of anticoagulation. The authors (1) claim that the early advantage of the higher dose (10 mg) of warfarin is a later reduction in factor VII evens rather than in factor II and X flats which are actually thought to be responsible for antithrombotic activity. (1) The same researchers repeated the studious mood and obtained similar results with a form into groups of 52 inpatients, most of whom also were receiving heparin. (2) Neither of these studies (12) examined clinically important results such as the likelihood of death, returning venous thromboembolism, or bleeding.

A larger, more late study (3) compared the use of 5-mg and 10-mg warfarin initiation algorithms in a collection of 201 patients with acute venous thromboembolism. The authors used an adaptation of an algorithm for initiating 5-mg warfarin therapy, (4) choosing the higher value in each range for the warfarin dose for a given INR range. Patients were simultaneously anticoagulated with dalteparin or tinzaparin for at least five days, and patients requiring hospitalization were exclud from the inquiry (3)

The mean age of patients was 55 years, and approximately 25 percent had cancer. There were more men in the 10-mg collection than in the 5-mg dispose (65 out of 104 patients versus 47 gone out of 97 patients, respectively), nevertheless this finding is of uncertain clinical significance. (3) Overall, efficacy was significantly better in patients receiving 10 mg of warfarin than in those receiving 5 mg with a faster time to a mean INR greater than 19 (42 versus 56 days, respectively; P < 001); more patients at therapeutic flats by day 5 (83 versus 46 percent respectively; P < 001); and no difference in the percentage of patients with an INR of at least 50 in the first four weeks (9 versus 11 percent respectively; P > 2)

There was no significant difference between the brace groups in the likelihood of major bleeding episodes (one patient in each group) or death (none in the 10-mg cluster and one in the 5-mg group) yet there was a possible stretch toward more episodes of renewed venous thromboembolism at 90 days (three patients in those receiving 10 mg versus none in those receiving 5 mg; P = 09)

Thus, couple studies (1,2) support a 5-mg warfarin initiation algorithm, while a larger, more latter study (3) supports a 10-mg algorithm. The difference may be partially explained by way of disparities in patient populations: the 5-mg algorithm appeared to work better in form into groupss of inpatients who also were receiving heparin, (12) while the 10-mg algorithm performed better in outpatients who also were receiving low-molecular-weight heparin. (3) In addition, the more newly come study (3) that reported more rapid anticoagulation with a 10-mg algorithm used a somewhat more aggressive algorithm than the brace older, smaller studies (1,2) that did not find a benefit with this dosage. For example, a patient with an INR of 12 onward day 3 would receive 15 mg of warfarin in succession days 3 and 4 with the newer algorithm (3) and merely 5 or 10 mg with the older algorithms. (12) Unles recently made known data demonstrate that one or the other of these algorithms is definitely better, the couple should be considered reasonable options in the initiation of warfarin therapy. (5)

Another subject of attention (6) based on an initial 5-mg dose provides data that help predict the eventual maintenance dosage of warfarin. The authors identified a consecutive collection of 91 patients with nonvalvular atrial fibrillation who required anticoagulation as outpatients. They were not receiving heparin. Patients were given 5 mg of warfarin by day for four days, and the INR was measured forward day 5. Their final maintenance dosage was established according to following them for three month and the relationship between their INR forward day 5 and their stable maintenance dose (target INR: 20 to 30) was graphed as a nomogram. (6) The estimate was touchstoneed prospectively on a group of 23 patients, with a mean difference between the predicted and final actual dosage of single 1.6 mg per week (95 percent confidence interval [CI], 00007 to 3195)